^
Association details:
| Biomarker: | BLM mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
Published date:
05/13/2020
Excerpt:
Patients received olaparib 300 mg...Responses were gene specific (Table): gPALB2 and sBRCA mutations predicted response…
DOI:
10.1200/JCO.2020.38.15_suppl.1002
Trial ID:
